RecruitingNCT05981274

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

A Prospective and Retrospective Interventional Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Sponsor

Tri-Service General Hospital (TSGH)

Enrollment

45 participants

Start Date

Jul 14, 2023

Study Type

OBSERVATIONAL

Conditions

Severe Hemophilia A Without Inhibitor

Summary

Study Objectives\* 1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A 2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health. 3. Compare the clinical outcomes from 1 year before and after switching to EHL. 4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying serum biomarker. for people with severe hemophilia a without inhibitor. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTserum biomarker.

serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)

Locations(1)

Tri-Service General Hospital Hemophilia Care Center

Taipei, Neihu Dist., Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05981274

Related Trials

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

NCT058028361 location